Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma

The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status

(2014) M. Foglietta et al.   HAEMATOLOGICA

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma

(2014) James Favaloro et al.   LEUKEMIA & LYMPHOMA

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells

(2013) J. H. Myklebust et al.   BLOOD

Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

(2013) T. J. Kearl et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow

(2013) I. R. Ramachandran et al.   JOURNAL OF IMMUNOLOGY

The Systemic Cytokine Environment Is Permanently Altered in Multiple Myeloma

(2013) Mary M. Zheng et al.   PLoS One

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma

(2012) J. Richter et al.   BLOOD

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Vγ9Vδ2 T cell-based immunotherapy in hematological malignancies: from bench to bedside

(2011) Barbara Castella et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Chronic Virus Infection Enforces Demethylation of the Locus that Encodes PD-1 in Antigen-Specific CD8+ T Cells

(2011) Ben Youngblood et al.   IMMUNITY

Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between V 9V 2 T Cells,    CD8+ T Cells, Regulatory T Cells, and Dendritic Cells

(2011) B. Castella et al.   JOURNAL OF IMMUNOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma

(2011) S K Martin et al.   LEUKEMIA

Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors

(2011) Shu-Fang Wang et al.   PLoS One

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens

(2010) Masashi Iwasaki et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

(2008) Pellegrino Musto et al.   CANCER

Relationship between CD107a expression and cytotoxic activity

(2008) Esin Aktas et al.   CELLULAR IMMUNOLOGY

Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+ CD25+ FoxP3+regulatory T cells

(2008) Volker Kunzmann et al.   IMMUNOLOGY